Relapsed/Refractory AL Amyloidosis
Search documents
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Globenewswire· 2025-10-14 12:45
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA. Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time. The Company will be available for one-on-on ...